Haizheng pharmaceutical industry joins hands with Sanofi to explore new diabetes treatment
-
Last Update: 2015-07-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, Zhejiang Haizheng Pharmaceutical Co., Ltd announced that the CEO of the company and Sanofi signed a memorandum of non binding Cooperation (hereinafter referred to as the memorandum) to explore potential cooperation in the field of diabetes treatment Cooperation may include the establishment of a joint venture in China for the development, production and / or commercialization of insulin, insulin analogues and any other diabetes therapies agreed by the parties It is worth noting that the memorandum signed this time is only an expression of the current intention of both parties and is not legally binding Both parties shall conduct due diligence on each other within the scope of cooperation after signing the memorandum Sanofi is one of the world's leading enterprises in the field of diabetes, with diabetes sales reaching $10.7 billion last year Lantus, the world's best-selling drug, lost patent protection in the United States in February, with sales of $7 billion in 2014 If Haizheng can "marry" Sanofi, it will be a good move in the field of diabetes.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
